Roche extends hostile bid for Ventana
This article was originally published in The Gray Sheet
Executive Summary
Tissue-based cancer test firm Ventana continues to dismiss Roche's $3 billion unsolicited takeover offer as "grossly inadequate" after Roche extends its $75-per-share bid for a third time on Sept. 19 - this time until Nov. 1. The offer, launched in June, had been slated to expire Sept. 20. The 63,500 Ventana shares tendered to date represent just 0.19% of the company (1"The Gray Sheet" Aug. 27, 2007, In Brief)
You may also be interested in...
Roche’s Ventana bid advances in court
Ventana Medical Systems is preliminarily enjoined from using certain anti-takeover provisions to avert Roche's $3 billion hostile bid for the Tucson-based cancer diagnostics firm under an Arizona federal district court decision Aug. 21. Swiss firm Roche launched its $75-per-share tender offer for Ventana June 27, and has extended the offer's expiration date from Aug. 23 to Sept. 20. The offer represents a 44% premium over Ventana's last stock closing price before the bid was announced, although the market price has since soared as high as $88. Ventana says it remains "steadfast" in its belief that Roche's bid is "wholly inadequate" (1"The Gray Sheet" July 2, 2007, p. 10)...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.